×

Serwis używa ciasteczek ("cookies") i podobnych technologii m.in. do utrzymania sesji i w celach statystycznych. • Ustawienia przeglądarki dotyczące obsługi ciasteczek można swobodnie zmieniać. • Całkowite zablokowanie zapisu ciasteczek na dysku komputera uniemożliwi logowanie się do serwisu. • Więcej informacji: Polityka cookies OPI PIB


  • Tytuł artykułu:
    Herbal medicines with anti-anxiety and antidepressant activity
  • Opublikowany w czasopiśmie:
  • Rocznik 2009,  tom 55,  numer 1
  • 84-97
  • Artykuł przeglądowy
  • polski
  • article-8ac3a516-161e-4a28-a7bc-966876167991
  • 09.10.2015 17:11:41
  • Gerard Nowak [1]
  • [1] Department of Medicinal and Cosmetic Natural Products, Poznań University of Medical Sciences, Poland
  • Brak afiliacji
Nie znaleziono publikacji cytujących ten artykuł
  1. Weiss RF, Fintelmann V. 2nd ed. Stuttgart, New York, Thieme 2000:261.
  2. World Health Organization. ICD-10, International Statistical Classification of Disearse and Related Health Problems. Tenth Revision. Geneva: WHO 1992.
  3. Małyszczak K, Pawłowski T. Zespoły lękowo-depresyjne. Patogeneza, obraz kliniczny i leczenie. Akademia Medyczna im. Piastów Śląskich we Wrocławiu. Wrocław 2007:17-23.
  4. Stein MB, Kirk P, Prabhn V. Mixted anxiety-depresion in a primary care clinic. J Affect Disord 1995; 34:78-94.
  5. Dressing H. Baldrian-Melisse-Kombinationen versus Benzodiazepin, Therapiewoche 1982; 12:728-36.
  6. Lutomski J. Ziołolecznictwo. Tradycja i przyszłość, Tower Press, Gdańsk 2003:73:4.
  7. Hendriks H, Bos R, Allersma DP, Malinge TK, Koster AS. Pharmacological screaning of valerenal and some over compounds of essential oil of Valeriana officinalis. Planta Med. 1981; 42:62-8.
  8. Blumenthal M, Goldberg A, Brinckann J. Herbal Medicine. Expanded Commission E Monographs. Valerian root.1st ed. American Botanical Council. Newton 2000:394-400.
  9. Hattesoht M, Fejster B, Sievers H, Lehnifeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. 2008; 15:2-15.
  10. Schultz H, Jobert M, Hubner WD. The Quantitaive EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine. 1998; 5:449-58.
  11. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Valerianae Radix. 2nd ed. Thieme. Nortfolk 2003: 539-46.
  12. EMEA. European Medicines Agency. Evaluation of Medicines for Human Use. Valeriana officinalis. London 2006.
  13. Koch-Heitzmann R, Schultze W. 2000 Jahre Melissa officinalis, , Zeitschift fur Phytotherapie 1988; 9:77-85
  14. Borkowski B. Roślinne środki farmaceutyczne stosowane w dolegliwościach układu nerwowego. Farmacja Polska 1997; 53:781-91.
  15. Blumenthal M, Goldberg A, Brinckann J. Herbal Medicine. Expanded Commission E Monographs. Lemon balm.1st ed. American Botanical Council. Newton. 2000:250-2.
  16. Kennedy DO, Scholey AB. Modulation of mood and cognitive performance following acute administration of Melissa officinalis, Pharmacol Biochem Behav 2002; 72:953-64.
  17. Kennedy DO, Little W. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis. Psychosom Med 2004; 66:607-13.
  18. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Melissae folium. 2nd ed. Thieme, Nortfolk 2003:324-7.
  19. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Passiflorae Herba. 2nd ed. Thieme, Nortfolk 2003:359-64.
  20. Speroni E, Billi R, Mercati V, Boncompagni E, Toja E. Sedative effects of crude extract of Passflora incarnata after oral administartion. Phytother Res 1996; 10:592-4.
  21. Galiano G, Foussard-Blampin O, Bretaudeau J. Etude experimentale du role dans les properietes psycho-pharmacologiques de Passiflora incarnate L.(Passifloraceas) Phytother 1994; 40/41:18-22.
  22. Akhonzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Rhani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam.J Clin Pharm Therap 2001; 26:363-7.
  23. EMEA. European Medicines Agency. Evaluation of Medicines for Human Use. Passiflora IncarnataL. Herba, London 2007.
  24. Lee KM, Jung JS, Song DK, Kim YH. Effects of Humulus lupulus extracts on the central nervous system in mice. Planta Med 1993; 59 (Suppl.).
  25. Wohlfart R, Hansel R, Schmidt H. Nachweis sedative-hypnotischer Wirkstoffe im Hopfen. 4. Mitteilung. Die Pharmakologie des Hopfeninhalssstofles 2-methyl-3-buten-2-ol. Planta Med 1983; 48:120-3.
  26. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Lupuli flos. 2nd ed. Thieme, Nortfolk 2003:306-11.
  27. Blumenthal M, Goldberg A, Brinckann J. Herbal Medicine. Expanded Commission E Monographs.Lavender Flower. 1st ed. American Botanical Council. Newton 2000:226-9.
  28. Gleitz J, Beile A, Peters T. (+,-)-Kavain inhibits veratridine activated and KCl induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology 1996; 315:179-86.
  29. Warnecke G. Langezeittherapie psychischer und vegetativer Dysregulationen mit Zubereitungen aus Piper methysticum. Erfahrungsheilkunde 1989; 6:333-8.
  30. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Piperis Methystici rhizome. 2nd ed. Thieme. Nortfolk. 2003:365-82.
  31. Lehmann E, Kinzler E, Friedmann J. Efficacy of a special kava extract (Piper mathysticum) in patient with states of anxiety, tensionand excitedness, of a nonmental origin: a double-blind placebo controlled study of four weeks treatment. Phytomedicine 1996; 3:113-19.
  32. Volz HP, Kiesser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: A randomized placebo-controlled 25 weeks outpatient trial. Pharmacopsychiatry 1997; 30:1-5.
  33. Heinze HJ, Munthe TF, Steitz J, Matzke M. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopychiatry 1994; 27:224-30.
  34. Gessner B, Cnota P. Extract of kava-kava rhizome in comparison with diazepam and placebo. Z Phtytother 1994; 15:30-7.
  35. Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID. Effects of heavy usage of kava-kava on physical health: summary of a pilot survey in an Aborignal community. Med J Aust 1988; 148:548-55.
  36. Blumenthal M, Goldberg A, Brinckann J. Herbal Medicine. Expanded Commission E Monographs. Linden Flower. 1st ed. American Botanical Council. Newton 2000:240-43.
  37. Foster S, Tyler VE. Tyler’s Honest Herbal. The Haworth Herbal Press. New York, London 1999:247-8.
  38. Blumenthal M, Goldberg A, Brinckann J. Herbal Medicine. Expanded Commission E Monographs. Mothewort Herb. 1st ed. American Botanical Council. Newton. 2000:267-9.
  39. Weiss RF, Fintelmann V. 2nd ed. Stuttgart, New York, Thieme 2000:270.
  40. Thiede H-M, Walper A. MAO- und COMT- Hemmung durch Hypericum-Extracte. Nevenheilkunde. 1993;12:346-8.
  41. Wonnemann M, Singer A, Müller W.E. Inhibition of synaptosomal uptake of 3 by hiperforin, a major constituent of St. John’s wort: the role amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000; 23:188-97.
  42. Butterweck V, Böckers T, Korte B, Witkowski W, Winterfoff H. Long-term effects of St. John’s wort and hipericin on monoamine levels in rat hypophtalamus and hippocampus. Brain Res 2002; 930:21-9.
  43. Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholoamines, serotonin and glutamate in the rat locus coeruleus. Neurosti Lett. 1999; 262:199-202.
  44. ESCOP Monographs: European Scientific Cooperative On Phytotherapy. Hyperici Herba. 2nd ed. Thieme. Nortfolk. 2003:257-81.
  45. Ruschitzka F, Meier PJ, Turina M, Lüscher TF. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355:548-9.
  • Ruschitzka F, Meier PJ, Turina M, Lüscher TF. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355:548-9. - Lancet
  • Volz HP, Kiesser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: A randomized placebo-controlled 25 weeks outpatient trial. Pharmacopsychiatry 1997; 30:1-5. - Pharmacopsychiatry
  • Speroni E, Billi R, Mercati V, Boncompagni E, Toja E. Sedative effects of crude extract of Passflora incarnata after oral administartion. Phytother Res 1996; 10:592-4. - PHYTOTHER RES
  • Kennedy DO, Little W. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis. Psychosom Med 2004; 66:607-13. - PSYCHOSOM MED
  • Gleitz J, Beile A, Peters T. (+,-)-Kavain inhibits veratridine activated and KCl induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology 1996; 315:179-86. - Neuropharmacology
  • Hendriks H, Bos R, Allersma DP, Malinge TK, Koster AS. Pharmacological screaning of valerenal and some over compounds of essential oil of Valeriana officinalis. Planta Med. 1981; 42:62-8. - PLANTA MED
  • Lehmann E, Kinzler E, Friedmann J. Efficacy of a special kava extract (Piper mathysticum) in patient with states of anxiety, tensionand excitedness, of a nonmental origin: a double-blind placebo controlled study of four weeks treatment. Phytomedicine 1996; 3:113-19. - Phytomedicine
  • Lee KM, Jung JS, Song DK, Kim YH. Effects of Humulus lupulus extracts on the central nervous system in mice. Planta Med 1993; 59 (Suppl.). - PLANTA MED
  • Wonnemann M, Singer A, Müller W.E. Inhibition of synaptosomal uptake of 3 by hiperforin, a major constituent of St. John’s wort: the role amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000; 23:188-97. - NEUROPSYCHOPHARMACOL